Title:
COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B-TARGETED THERAPY
Document Type and Number:
WIPO Patent Application WO/2019/060542
Kind Code:
A3
Abstract:
This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).
Inventors:
MOSHER REBECCA (US)
POLING LAURA (US)
BERGSTROM DONALD (US)
POLING LAURA (US)
BERGSTROM DONALD (US)
Application Number:
PCT/US2018/051951
Publication Date:
May 02, 2019
Filing Date:
September 20, 2018
Export Citation:
Assignee:
MERSANA THERAPEUTICS INC (US)
International Classes:
G01N33/574; A61K47/68; C07K16/30
Domestic Patent References:
| WO2017068097A1 | 2017-04-27 |
Foreign References:
| US8603474B2 | 2013-12-10 | |||
| EP2423232A1 | 2012-02-29 |
Other References:
IBERE CAUDURO SOARES ET AL: "In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35", APPLIED IMMUNOHISTOCHEMSITRY AND MOLECULAR MORPHOLOGY, vol. 20, no. 2, 1 March 2012 (2012-03-01), US, pages 165 - 172, XP055532979, ISSN: 1541-2016, DOI: 10.1097/PAI.0b013e318228e232
GERBER DE, INFANTE JR, GORDON MS, SCHILLER JH, SPIGEL D, WANG Y ET AL.: "Safety, Pharmacokinetics, and Activity of the Anti-NaPi2bAntibody-Drug Conjugate DNIB0600A: A Phase I Study inPatients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer", 15 October 2013 (2013-10-15), XP002787350, Retrieved from the Internet [retrieved on 20181211]
K. LIN ET AL: "Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers", CLINICAL CANCER RESEARCH, vol. 21, no. 22, 8 July 2015 (2015-07-08), US, pages 5139 - 5150, XP055373355, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-3383
NATALYA BODYAK ET AL: "Abstract 1194: Discovery and preclinical development of a highly potent NaPi2b-targeted antibody -drug conjugate (ADC) with significant activity in patient -derived non -small cell lung cancer (NSCLC) xenograft models", AACR 107TH ANNUAL MEETING 2016; APRIL 16-20, 2016; NEW ORLEANS, LA, vol. 76(Suppl.14), 1 July 2016 (2016-07-01), XP055533120, DOI: 10.1158/1538-7445.AM2016-1194Published
REBECCA MOSHER ET AL: "Abstract B119: Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models", AACR-NCI-EORTC INTERNATIONAL CONFERENCE: MOLECULAR TARGETS AND CANCER THERAPEUTICS, vol. 17(S1), 1 January 2018 (2018-01-01), XP055533090, DOI: 10.1158/1535-7163.TARG-17-B119Published
GERBER DE, INFANTE JR, GORDON MS, SCHILLER JH, SPIGEL D, WANG Y ET AL.: "Safety, Pharmacokinetics, and Activity of the Anti-NaPi2bAntibody-Drug Conjugate DNIB0600A: A Phase I Study inPatients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer", 15 October 2013 (2013-10-15), XP002787350, Retrieved from the Internet
K. LIN ET AL: "Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers", CLINICAL CANCER RESEARCH, vol. 21, no. 22, 8 July 2015 (2015-07-08), US, pages 5139 - 5150, XP055373355, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-3383
NATALYA BODYAK ET AL: "Abstract 1194: Discovery and preclinical development of a highly potent NaPi2b-targeted antibody -drug conjugate (ADC) with significant activity in patient -derived non -small cell lung cancer (NSCLC) xenograft models", AACR 107TH ANNUAL MEETING 2016; APRIL 16-20, 2016; NEW ORLEANS, LA, vol. 76(Suppl.14), 1 July 2016 (2016-07-01), XP055533120, DOI: 10.1158/1538-7445.AM2016-1194Published
REBECCA MOSHER ET AL: "Abstract B119: Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models", AACR-NCI-EORTC INTERNATIONAL CONFERENCE: MOLECULAR TARGETS AND CANCER THERAPEUTICS, vol. 17(S1), 1 January 2018 (2018-01-01), XP055533090, DOI: 10.1158/1535-7163.TARG-17-B119Published
Attorney, Agent or Firm:
ERLACHER, Heidi et al. (US)
Download PDF:
Previous Patent: USE OF CXCL12 TO PROMOTE SURVIVAL, FUNCTION, AND IMMUNOISOLATION OF STEM CELL-DERIVED BETA CELLS
Next Patent: STABILIZED CAMERA SYSTEM
Next Patent: STABILIZED CAMERA SYSTEM